首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   166924篇
  免费   16024篇
  国内免费   7576篇
耳鼻咽喉   2280篇
儿科学   3878篇
妇产科学   1827篇
基础医学   30264篇
口腔科学   5333篇
临床医学   12970篇
内科学   22864篇
皮肤病学   4434篇
神经病学   9155篇
特种医学   3701篇
外国民族医学   118篇
外科学   15206篇
综合类   26029篇
现状与发展   49篇
预防医学   4357篇
眼科学   3469篇
药学   12884篇
  25篇
中国医学   5132篇
肿瘤学   26549篇
  2024年   132篇
  2023年   2372篇
  2022年   2975篇
  2021年   5784篇
  2020年   5430篇
  2019年   5328篇
  2018年   5519篇
  2017年   5779篇
  2016年   6054篇
  2015年   6895篇
  2014年   10023篇
  2013年   11090篇
  2012年   9577篇
  2011年   10714篇
  2010年   8910篇
  2009年   8537篇
  2008年   8994篇
  2007年   9217篇
  2006年   8358篇
  2005年   7679篇
  2004年   6814篇
  2003年   5906篇
  2002年   4853篇
  2001年   4172篇
  2000年   3422篇
  1999年   2976篇
  1998年   2454篇
  1997年   2417篇
  1996年   2093篇
  1995年   2125篇
  1994年   1878篇
  1993年   1565篇
  1992年   1276篇
  1991年   1185篇
  1990年   921篇
  1989年   866篇
  1988年   811篇
  1987年   648篇
  1986年   604篇
  1985年   795篇
  1984年   716篇
  1983年   492篇
  1982年   517篇
  1981年   418篇
  1980年   347篇
  1979年   259篇
  1978年   184篇
  1977年   144篇
  1976年   107篇
  1975年   47篇
排序方式: 共有10000条查询结果,搜索用时 62 毫秒
61.
BackgroundPatients' inflammatory history is an important factor underlying red blood cell (RBC) alloimmunization, which is a frequent transfusion complication among individuals with sickle cell disease (SCD). HLA-G has been associated with different inflammatory and auto - immune diseases. Our goal was to verify whether the HLA-G + 3142 C>G and 14-bp Ins/Del variations are associated with RBC antibody development among SCD patients.MethodsThis was a single-center case-control study. SCD patients were randomly selected for the study and divided into two groups: ‘Alloimmunized’ and ‘Nonalloimmunized’ depending on the presence of irregular antibodies. The ‘Alloimmunized’group was further divided into two subgroups according to the presence of only antibodies against the Rh and Kell blood group systems or the existence of antibodies to antigens of the other blood group systems.ResultsA total of 213 patients were included in the study (110 alloimmunized and 103 non-alloimmunized). The ‘Alloimmunized’ and ‘Non-alloimmunized’ groups did not differ statistically regarding the HLA-G + 14 bp Ins/Del ( p = 0.494) and + 3142 C>G ( p = 0.334). Individuals who had only antibodies against the Rh and Kell antigens had a frequency of HLA-G + 3142GG genotype almost twice as high compared to the groupwith antibodies against less immunogenic antigens ( p = 0.043).ConclusionsThe genotype frequency of HLA-G + 3142 C>G differs among alloimmunized SCD patients, depending on the presence of antibodies against low immunogenic RBC antigens. This highlights a possible role played by the HLA-G molecule in the RBC alloimmunization process.  相似文献   
62.
63.
ObjectivesMap regional lymph node metastases for lateralized oral cavity squamous cell carcinoma (OCSCC) and evaluate factors associated with regional metastases and recurrence.Materials and methodsRetrospective cohort study of 715 patients with lateralized OCSCC surgically treated in 1997–2011. Analysis was performed using log-rank, Kaplan-Meier, and multivariable logistic and Cox regression.ResultsRegional metastases were identified in ipsilateral levels IIA (24%), IB (18%), III (13%), V (9%), IV (7%), IA (2%) and IIB (1%) and the contralateral neck (3%). Lymphovascular invasion (LVI) (Hazard Ratio [HR] 2.2, 95% Confidence Interval [CI] 1.2–3.9) and T category (T3 vs. T1: HR 4.1, 95% CI 1.9–9.3; T4 vs. T1: HR 2.3, 95% CI 1.2–4.3) were associated with regional metastases. Most (71%) isolated regional metastatic recurrences were in undissected levels of the neck, including 58% in levels IV and V. Tumors of the hard palate (HR 4.3, 95% CI 1.2–16.1), upper alveolus (HR 3.2, 95% CI 1.0–4.7) or with LVI (HR 2.0, 95% CI 1.0–3.9) were associated with isolated regional recurrence. For upper alveolar/hard palate tumors, depth of invasion (DOI) ≥4 mm (P = .003) and LVI (P = .04) were associated with regional metastases.ConclusionsFor lateralized OCSCC, elective neck dissection of level IIB or the contralateral neck may rarely be needed, but additional surgical or radiation treatment of levels IV and V may be considered based on patient risk factors, including T category 3–4 or LVI. For upper alveolar/hard palate tumors, DOI ≥4 mm is an appropriate threshold for elective neck dissection.  相似文献   
64.
65.
66.
67.
ObjectivesTo determine the anti-inflammatory effects of green tea catechins in immortalized human gingival epithelial cells (Ca9-22) stimulated with Porphyromonas gulae lipopolysaccharide (LPS).MethodsCa9-22 cells were incubated with P. gulae LPS (10 μg/ml) with or without green tea catechins, epigallocatechin-3-gallate (EGCg), epigallocatechin (EGC), epicatechin-3-gallate (ECG), and epicatechin (EC) (each at 50 μM), for 6 or 24 h. Real-time polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay were used to determine the induction of cyclooxygenase 2 (COX2), tumor necrosis factor alpha (TNF-ɑ), interleukin 6 (IL-6), and IL-8. Furthermore, the expression of toll-like receptors (TLRs) 2 and 4 was examined using real-time PCR and western blotting analysis, and phosphorylation of the p38 and ERK1/2 was examined using western blotting analysis.ResultsAt the mRNA and protein levels, EGCg, EGC, ECG, and EC were found to significantly inhibit COX2, TNF-ɑ, IL-6, and IL-8. Furthermore, the levels of ERK1/2 and p38 phosphorylation induced by P. gulae LPS were decreased following the addition of each of the catechins, as well as TLR2 and 4 mRNA and protein.ConclusionsThese findings indicate that green tea catechins are potent inhibitors of in?ammatory responses induced by P. gulae LPS, and may also be useful for prevention and/or attenuation of periodontitis.  相似文献   
68.
1文献来源Jabbour SK,Lee KH,Frost N,et al.Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable,locally advanced,stageⅢnon?small cell lung cancer.The phase 2 KEYNOTE?799 nonrandomized trial[J].JAMA Oncol,2021,7(9):1-9.  相似文献   
69.
70.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号